

Benedikt Schaefer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1768236/publications.pdf>

Version: 2024-02-01

39
papers

1,125
citations

394421

19
h-index

434195

31
g-index

41
all docs

41
docs citations

41
times ranked

1500
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-11 drives human and mouse alcohol-related liver disease. <i>Gut</i> , 2023, 72, 168-179.	12.1	13
2	Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 978-987.e2.	4.4	12
3	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. <i>Gut</i> , 2022, 71, 415-423.	12.1	28
4	Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. <i>Bone</i> , 2022, 154, 116202.	2.9	40
5	Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1009-1019.	3.6	20
6	A proteomic survival predictor for COVID-19 patients in intensive care. , 2022, 1, e0000007.		28
7	Synonymous mutation in adenosine triphosphatase copper-transporting beta causes enhanced exon skipping in Wilson disease. <i>Hepatology Communications</i> , 2022, 6, 1611-1619.	4.3	6
8	EASL Clinical Practice Guidelines on haemochromatosis. <i>Journal of Hepatology</i> , 2022, 77, 479-502.	3.7	49
9	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	2.9	46
10	Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans. <i>Gut</i> , 2021, 70, 585-594.	12.1	6
11	Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2256-2273.	2.4	61
12	Dual proteotoxic stress accelerates liver injury via activation of μ 62 α -Nrf2. <i>Journal of Pathology</i> , 2021, 254, 80-91.	4.5	1
13	Dynamic Î±-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2021, 156, 559.	4.3	34
14	MRI-Based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of Non-Homeostatic Iron Regulator Hemochromatosis Genes. <i>Hepatology</i> , 2021, 74, 2424-2435.	7.3	8
15	A time-resolved proteomic and prognostic map of COVID-19. <i>Cell Systems</i> , 2021, 12, 780-794.e7.	6.2	125
16	Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant. <i>JAMA Surgery</i> , 2021, 156, e213112.	4.3	30
17	Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. <i>Journal of Viral Hepatitis</i> , 2020, 27, 188-194.	2.0	20
18	Liver Phenotypes of European Adults Heterozygous or Homozygous for Piâ—Z Variant of AAT (Piâ—MZ vs) Tj ETQq0,0 0 rgBT /Overlock	1.3	63

#	ARTICLE	IF	CITATIONS
19	Hypophosphatemia in children treated with ferric carboxymaltose. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2020, 109, 1491-1492.	1.5	11
20	Intravenous iron supplementation therapy. <i>Molecular Aspects of Medicine</i> , 2020, 75, 100862.	6.4	44
21	Reply. <i>Liver Transplantation</i> , 2019, 25, 344-345.	2.4	0
22	Reply. <i>Liver Transplantation</i> , 2019, 25, 1287-1288.	2.4	0
23	Iron Matryoshka—Haemochromatosis nested in Ferroportin Disease?. <i>Liver International</i> , 2019, 39, 1014-1015.	3.9	4
24	Management of patients with chronic hepatitis C failing repeated courses of interferon-free direct acting antiviral combination therapy. <i>GastroHep</i> , 2019, 1, 76-83.	0.6	5
25	Classical and intermediate monocytes scavenge non-transferrin-bound iron and damaged erythrocytes. <i>JCI Insight</i> , 2019, 4, .	5.0	42
26	Heterozygosity for the alpha ₁ -antitrypsin Z allele in cirrhosis is associated with more advanced disease. <i>Liver Transplantation</i> , 2018, 24, 744-751.	2.4	58
27	Transferrin as a predictor of survival in cirrhosis. <i>Liver Transplantation</i> , 2018, 24, 343-351.	2.4	27
28	Con: Liver transplantation for expanded criteria malignant diseases. <i>Liver Transplantation</i> , 2018, 24, 104-111.	2.4	18
29	Liver transplantation for hilar cholangiocarcinoma (h-CCA): is it the right time?. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 38-38.	3.0	6
30	Impact of patatin-like phospholipase domain containing rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 451-459.	3.7	26
31	Disease burden of hepatitis C in the Austrian state of Tyrol—Epidemiological data and model analysis to achieve elimination by 2030. <i>PLoS ONE</i> , 2018, 13, e0200750.	2.5	6
32	Liver disease in adults with alpha ₁ -antitrypsin deficiency. <i>United European Gastroenterology Journal</i> , 2018, 6, 710-718.	3.8	23
33	CCBE1 mutation causing sclerosing cholangitis: Expanding the spectrum of lymphedema-cholestasis syndrome. <i>Hepatology</i> , 2017, 66, 286-288.	7.3	6
34	Blood and Bone Loser. <i>Gastroenterology</i> , 2017, 152, e5-e6.	1.3	20
35	Iron-induced hypophosphatemia. <i>Current Opinion in Nephrology and Hypertension</i> , 2017, 26, 266-275.	2.0	121
36	Letter: inconsistency in reporting of hypophosphatemia after intravenous iron. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 641-643.	3.7	7

#	ARTICLE	IF	CITATIONS
37	Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk. PLoS ONE, 2016, 11, e0167146.	2.5	68
38	First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: Complete remission followed by lethal sepsis. Liver Transplantation, 2014, 20, 1145-1148.	2.4	9
39	Iron metabolism in transplantation. Transplant International, 2014, 27, 1109-1117.	1.6	32